Publications - Debiopharm

Publications

17 April 2012
A Phase I-II evaluation of the safety and efficacy of the oral HSP90 inhibitor Debio 0932 in combination with Standard of Care in first- and second-line therapy of Stage IIIb or IV NSCLC – The HALO study (HSP90 inhibition And Lung cancer Outcomes)
01 December 2009
Triptorelin 6-Month Formulation in the Management of Patients with Locally Advanced and Metastatic Prostate Cancer
11 June 2009
The cyclophilin inhibitor Debio 025 normalizes mitochondrial function, muslce apoptosis and ultrastructural defects in Col6a1-/- mypathic mice
08 May 2009
The Cyclophilin Inhibitor Debio 025 Combined with PEG IFNα2a Significantly Reduces Viral Load in Teatment-Naïve Hepatitis C Patients
23 February 2009
Evidence for lysophosphatidic acid 1 receptor signaling in the early phase of neuropathic pain mechanisms in experiments using Ki-16425, a lysophosphatidic acid 1 receptor antagonist

Older »

1/18

Debio 0932 ( 1 Article )
Debio 025 ( 37 Articles )
Triptorelin / Decapeptyl / Trelstar ( 7 Articles )
Oxaliplatin - Eloxatin - Elplat ( 12 Articles )
Debio 0614 ( 3 Articles )
Debio 0719 ( 6 Articles )
Debio 9902 - ZT-1 ( 8 Articles )
Debio 8609 Sanvar ( 1 Article )
Archives ( 15 Articles )

Latest News

15 May 2012 Debiopharm and Vifor Pharma sign an exclusive agreement for the distribution and commercialization of Pamorelin® LA in Switzerland - A drug treatment for prostate cancer and endometriosis

16 February 2012 Debiopharm and Curis Announce Initiation of Phase Ib Expansion Study of HSP90 Inhibitor Debio 0932

09 November 2011 Augurix Diagnostics receives the 2011 ‘Debiopharm /Valais Award’ For its point-of-care diagnostic test for the early detection of Celiac disease

Debiopharm on

© 2012 Debiopharm Group